Cell Signaling Technology

Product Pathways - Tyrosine Kinase/ Adaptors

Epidermal Growth Factor (Human EGF) #9908

MW Source Purity
6 kDa Human Recombinant Protein

Description

The human EGF coding cDNA was obtained from human periodontal tissue mRNA, subcloned into a prokaryotic expression vector and expressed in E. coli. Epidermal Growth Factor (Human EGF) was purified and stored in PBS buffer containing 0.1% BSA.

Concentration and Specific Activity

100 µg/ml

Western Blotting

Western Blotting

Western blot analysis of extracts from A431 cells, untreated or EGF-stimulated (100 ng/ml for 2 minutes), using Phospho-EGF Receptor (Tyr1068) Antibody #2234 (upper) or EGF Receptor Antibody #2232 (lower).

Directions for Use

CST recommends using 50-100 ng/ml of Human EGF for stimulation of Human EGF signaling.

Background

Epidermal growth factor (EGF) is a small polypeptide hormone that has mitogenic properties in vivo and in vitro and effects the growth and/or differentiated of many cell types. EGF elicits biologic responses by binding to its cell surface receptor, which is a transmembrane glycoprotein containing a cytoplasmic protein tyrosine kinase (1,2). The binding of EGF to EGF receptor induces dimerization of the receptor, autophosphorylation and activation of downstream signaling components (3). The integrated biological responses to EGF signaling are pleiotropic, including mitogenesis or apoptosis, enhanced cell motility, protein secretion, and differentiation or dedifferentiation. In addition to being implicated in organ morphogenesis, maintenance and repair, upregulated EGF receptor signaling has been correlated with progression to invasion and metastasis in a wide variety of tumors. Thus, EGF receptor and its downstream signaling molecules are targets for therapeutic interventions in wound repair and cancer (4-6).

  1. Wells, A. (1999) Int. J. Biochem. Cell. Biol. 31, 637-643.
  2. Boulougouris, P. and Elder, J. (2001) Anticancer Res. 21, 2769-2775.
  3. Schlessinger, J. (2002) Cell 110, 669-672.
  4. Sarries, C. et al. (2002) Pharmacogenomics 3, 763-780.
  5. Lorimer, I.A. (2002) Curr. Cancer Drug Targets 2, 91-102.
  6. Ghaneh, P. et al. (2002) J. Hepatobiliary Pancreat. Surg. 9, 1-11.

Application References

Have you published research involving the use of our products? If so we'd love to hear about it. Please let us know!

Companion Products

Product Pathways

Drug Discovery Tools

Featured Technologies

Protein Classes